HARMONY BIOSCIENCES HOLDINGS
HRMYNASDAQ🏆 #1820 by market capEarnings Nov 4 · PreUS Equity
$38.49▲ $0.54 (+1.41%)
Pre-market · at closeTrack HRMY
Get earnings, price moves & breaking news on Telegram
24h▲ 1.4%
7d▲ 6.9%
14d▲ 0.7%
30d▼ 2.0%
ytd▲ 2.9%
1y▲ 31.3%
🏦Market Cap
$2.24B
Small Cap
📈Revenue Growth (YoY)
21.5%
Healthy
📊Gross Margin
75.4%
High
💵FCF Margin
37.0%
Strong
⚖️P/S Ratio
2.3x
Cheap
Otter Score
76
Strong
Trading Snapshot
- Day Range
- $37.39 – $38.50
- 52-Week Range
- $25.90 – $43.49
- Volume (shares)
- 38,024
- Avg Volume (shares)
- —
- Shares Outstanding
- 58.2M
- Next Earnings
- 2026-11-04
Fundamentals Snapshot
- Annual Revenue
- $868M
- Last Q Revenue
- $261M
- P/E Ratio
- 12.3
- P/S Ratio
- 2.3x
- EPS (TTM)
- $3.13
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +0.8%
HARMONY BIOSCIENCES HOLDINGS
HRMYFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$868M▲ +21.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
77.2%▼ −1.2% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$208M▲ +9.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$348M▲ +59.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
58.7M▲ +0.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$513M▲ +$241M YoY
StockOtter · stockotter.spaceAbout HARMONY BIOSCIENCES HOLDINGS
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Strong
76/100
Analyst Ratings
ⓘConsensus
Buy
17 analysts
Strong Buy4
Buy8
Hold4
Sell1
Strong Sell0
Ratings as of Oct 2026
Latest News & Updates
News unavailable.